Literature DB >> 1830318

Polyol pathway activity in nervous tissues of diabetic and galactose-fed rats: effect of dietary galactose withdrawal or tolrestat intervention therapy.

J Sredy1, D R Sawicki, R R Notvest.   

Abstract

Enhanced polyol pathway activity resulting in an accumulation of sorbitol and a depletion of myoinositol in nervous tissues has been proposed to be important in development of diabetic neuropathies. This investigation demonstrated that in two models of diabetic complications, streptozocin (STZ)-induced diabetic rats and galactose-fed rats, 5 weeks of disease led to an accumulation of sorbitol or galactitol, respectively, in three cranial nerves (the optic (II), trigeminal (V), and vagus (X) nerves), as well as the sciatic nerve, cerebral cortex, and retina. In both models, the cranial nerves and cerebral cortex contained lower levels of accumulated polyol than the sciatic nerve. In addition, myoinositol depletion was observed in the sciatic nerve only. In a second galactose-fed rat study, returning 5-week galactose-fed rats to a normal diet for 6 weeks led to complete elimination of galactitol from the optic nerve, sciatic nerve, and retina and normalization of the sciatic nerve myoinositol concentration. Similarly, continuing the galactose diet for 6 more weeks (ie, a total of 11 weeks) as well as administration of the aldose reductase inhibitor (ARI) tolrestat (20 and 40 mg/kg/day), caused the sciatic nerve to contain a normal myoinositol concentration and a galactitol concentration that was 95% below the level observed in galactose-fed controls. In the optic nerve and retina, tolrestat was less effective, resulting in 69-78% lower galactitol levels. In conclusion, these findings indicate that sorbitol and galactitol accumulate in cranial nerves, brain, and retina without a concomitant decrease in myoinositol. Either withdrawal of the galactose diet or intervention with tolrestat normalized polyol levels in the sciatic nerve.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1830318     DOI: 10.1016/0891-6632(91)90010-m

Source DB:  PubMed          Journal:  J Diabet Complications        ISSN: 0891-6632


  8 in total

1.  Impaired visual evoked potential and primary axonopathy of the optic nerve in the diabetic BB/W-rat.

Authors:  A A Sima; W X Zhang; P V Cherian; S Chakrabarti
Journal:  Diabetologia       Date:  1992-07       Impact factor: 10.122

2.  High glucose stimulates TNFα and MCP-1 expression in rat microglia via ROS and NF-κB pathways.

Authors:  Yi Quan; Chang-tao Jiang; Bing Xue; Shi-gong Zhu; Xian Wang
Journal:  Acta Pharmacol Sin       Date:  2011-02       Impact factor: 6.150

Review 3.  Cognitive dysfunction and diabetes mellitus.

Authors:  Christopher T Kodl; Elizabeth R Seaquist
Journal:  Endocr Rev       Date:  2008-04-24       Impact factor: 19.871

4.  Relationship of cerebrospinal fluid glucose metabolites to MRI deep white matter hyperintensities and treatment resistance in bipolar disorder patients.

Authors:  William T Regenold; K Calvin Hisley; Pornima Phatak; Christopher M Marano; Abraham Obuchowski; David M Lefkowitz; Amritpal Sassan; Sameer Ohri; Tony L Phillips; Narveen Dosanjh; Robert R Conley; Rao Gullapalli
Journal:  Bipolar Disord       Date:  2008-11       Impact factor: 6.744

Review 5.  The role of polyols in the pathophysiology of hypergalactosemia.

Authors:  G T Berry
Journal:  Eur J Pediatr       Date:  1995       Impact factor: 3.183

6.  The preventive effect of aldose reductase inhibition on diabetic optic neuropathy in the BB/W-rat.

Authors:  M Kamijo; P V Cherian; A A Sima
Journal:  Diabetologia       Date:  1993-10       Impact factor: 10.122

7.  Ribose-5-phosphate isomerase deficiency: new inborn error in the pentose phosphate pathway associated with a slowly progressive leukoencephalopathy.

Authors:  Jojanneke H J Huck; Nanda M Verhoeven; Eduard A Struys; Gajja S Salomons; Cornelis Jakobs; Marjo S van der Knaap
Journal:  Am J Hum Genet       Date:  2004-02-25       Impact factor: 11.025

8.  ASK1 modulates the expression of microRNA Let7A in microglia under high glucose in vitro condition.

Authors:  Juhyun Song; Jong Eun Lee
Journal:  Front Cell Neurosci       Date:  2015-05-20       Impact factor: 5.505

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.